Sommario

• Editorial

  • ·The Dawn of a New Era of Alzheimer’s Research and Drug Development

    Pagina :385-386

    Y. Hara, Howard M. Fillit

    
  • ·The Clinical Trials Alzheimer’s Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!

    Pagina :387

    Michael W. Weiner

    

• CTAD Task Force Paper

  • ·Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report

    Pagina :388-392

    Rema Raman, P. Aisen, M.C. Carillo, M. Detke, J.D. Grill, O.C. Okonkwo, M. Rivera-Mindt, M. Sabbagh, B. Vellas, M. Weiner, R. Sperling, CTAD Task Force

    Riassunto Riassunto Mappa Mappa
  • ·The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report

    Pagina :393-399

    Julien Delrieu, R.J. Bateman, J. Touchon, M. Sabbagh, J. Cummings

    Riassunto Riassunto Mappa Mappa  

• Original Research

  • ·Prediction of Cognitive Decline for Enrichment of Alzheimer’s Disease Clinical Trials

    Pagina :400-409

    A. Tam, C. Laurent, S. Gauthier, Christian Dansereau, Alzheimer’s Disease Neuroimaging Initiative

    Riassunto Riassunto Mappa Mappa   
  • ·Effects of Non-Invasive Brain Stimulation on Alzheimer’s Disease

    Pagina :410-424

    Lihua Gu, H. Xu, F. Qian

    Riassunto Riassunto Mappa Mappa   
  • ·Evaluation of the Feasibility, Safety and Efficacy of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in People Affected by Moderate to Severe Alzheimer’s Disease: A Double-Blind Masked Clinical Trial for Dose Finding

    Pagina :425-434

    Agustín Ruiz, D. Sánchez, A. Lafuente, G. Ortega, M. Buendía, J. Papasey, S.Y. Jimeno, F.P. Badia, M.E. Palacio, C. Abdelnour, F. Ramírez-Toraño, F. Maestú, M.E. Sáez, L. Tárraga, P.C. Dagnelie, M. Boada

    Riassunto Riassunto Mappa Mappa   
  • ·Subjective Cognitive Decline in a Registry Sample: Relation to Psychiatric History, Loneliness, and Personality

    Pagina :435-440

    Gretchen O. Reynolds, L. Manning, D. Kirn, H. Klein, O. Hampton, O. Burke, R. Buckley, D. Rentz, R. Sperling, G.A. Marshall, R.E. Amariglio

    Riassunto Riassunto Mappa Mappa
  • ·Increased Incident Alzheimer’s Disease among Individuals with Varicose Veins: A Population-Based Cohort Study

    Pagina :441-448

    Chun-Yu Cheng

    Riassunto Riassunto Mappa Mappa  
  • ·Association between Dietary Theobromine and Cognitive Function in a Representative American Population: A Cross-Sectional Study

    Pagina :449-457

    L. Gao, W. Ge, C. Peng, J. Guo, Ning Chen, Li He

    Riassunto Riassunto Mappa Mappa   
  • ·Mesenchymal Stem Cells Modulate SIRT1/MiR-134/GSK3β Signaling Pathway in a Rat Model of Alzheimer’s Disease

    Pagina :458-468

    O.A.R. Abozaid, M.W. Sallam, Esraa S.A. Ahmed

    Riassunto Riassunto Mappa Mappa  
  • ·A Conformational Variant of p53 (U-p53^AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease

    Pagina :469-479

    Simona Piccirella, L. Van Neste, C. Fowler, C.L. Masters, J. Fripp, J.D. Doecke, C. Xiong, D. Uberti, P. Kinnon

    Riassunto Riassunto Mappa Mappa   
  • ·Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats

    Pagina :480-490

    B. Souchet, M. Audrain, Y. Gu, M.F. Lindberg, N.S. Orefice, E. Rey, N. Cartier, N. Janel, L. Meijer, Jérôme Braudeau

    Riassunto Riassunto Mappa Mappa  
  • ·Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer’s Disease from Frontotemporal Lobar Degeneration

    Pagina :491-498

    Marion Ortner, O. Goldhardt, J. Diehl-Schmid, I. Yakushev, K. Lanz, D.M. Hedderich, E. Manuilova, M. Simon, J.-P. Weinberger, T. Grimmer

    Riassunto Riassunto Mappa Mappa  
  • ·Decreased Gray—White Matter Contrast of [¹¹C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea

    Pagina :499-506

    S. Ylä-Herttuala, M. Hakulinen, P. Poutiainen, J. Lötjönen, M. Könönen, H. Gröhn, R. Vanninen, H. Mussalo, T. Laitinen, Esa Mervaala

    Riassunto Riassunto Mappa Mappa  

• Review

  • ·Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease

    Pagina :507-522

    Sharon Cohen, J. Cummings, S. Knox, M. Potashman, J. Harrison

    Riassunto Riassunto Mappa Mappa  
  • ·Aging, Senescence, and Dementia

    Pagina :523-531

    Q. Behfar, A. Ramirez Zuniga, Pamela V. Martino-Adami

    Riassunto Riassunto Mappa Mappa  
  • ·Clinical Research Investigating Alzheimer’s Disease in China: Current Status and Future Perspectives Toward Prevention

    Pagina :532-541

    Q. Wang, F. Gao, L. Dai, J. Zhang, D. Bi, Yong Shen

    Riassunto Riassunto Mappa Mappa

• Brief Report

  • ·Site Readiness Framework to Improve Health System Preparedness for a Potential New Alzheimer’s Disease Treatment Paradigm

    Pagina :542-549

    M. Anderson, N. Sathe, Cate Polacek, J. Vawter, T. Fritz, M. Mann, P. Hernandez, M.C. Nguyen, J. Thompson, J. Penderville, M. Arling, S. Safo, R. Christopher

    Riassunto Riassunto Mappa Mappa  
  • ·What Matters to Patients with Alzheimer’s Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions

    Pagina :550-555

    F. Jessen, J. Georges, M. Wortmann, Samantha Benham-Hermetz

    Riassunto Riassunto Mappa Mappa
  • ·Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment

    Pagina :556-560

    C.G. Lyketsos, S.B. Roberts, Elaine K. Swift, A. Quina, G. Moon, I. Kremer, P. Tariot, H. Fillit, D.E. Bovenkamp, P.P. Zandi, J.G. Haaga

    Riassunto Riassunto Mappa Mappa

• Letter to the Editor

  • ·Early-Onset Type 2 Diabetes and Risk of Dementia

    Pagina :561

    Tomoyuki Kawada

    Mappa Mappa
  • ·Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”

    Pagina :562

    K. Wang, Hong Liu

    Mappa Mappa